KARIN 500 以色列 - 英文 - Ministry of Health

karin 500

unipharm ltd, israel - clarithromycin - coated tablets - clarithromycin 500 mg - clarithromycin - clarithromycin - karin is indicated in the treatment of infections caused by one or more susceptible organisms. lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. upper respiratory tract infections for example, sinusitis and pharyngitis. karin is also indicated in skin and soft tissue infections of mild to moderate severity.karin is also indicated in combination with proton pump inhibitor for the eradication of h.pylori in patients with proven duodenal ulcers. treatment of mycobacterium avium complex infection in aids patients

RODENAL 5 MG TABLETS 以色列 - 英文 - Ministry of Health

rodenal 5 mg tablets

rekah pharmaceutical industry ltd, israel - trihexyphenidyl hydrochloride - tablets - trihexyphenidyl hydrochloride 5 mg - tertiary amines - rodenal tablet is an adjunct medicine in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic), it is also indicated to control extrapyramidal disorders due to central nervous system drugs such as phenothiazines.

RODENAL 2 MG TBLETS 以色列 - 英文 - Ministry of Health

rodenal 2 mg tblets

rekah pharmaceutical industry ltd, israel - trihexyphenidyl hydrochloride - tablets - trihexyphenidyl hydrochloride 2 mg - tertiary amines - rodenal tablet is an adjunct medicine in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic), it is also indicated to control extrapyramidal disorders due to central nervous system drugs such as phenothiazines.

STATOR 10 以色列 - 英文 - Ministry of Health

stator 10

unipharm ltd, israel - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

STATOR 20 以色列 - 英文 - Ministry of Health

stator 20

unipharm ltd, israel - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 20 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

STATOR 40 以色列 - 英文 - Ministry of Health

stator 40

unipharm ltd, israel - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 40 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

STATOR 5 以色列 - 英文 - Ministry of Health

stator 5

unipharm ltd, israel - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 5 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia ) or mixed dyslipidaemia ( type iib ) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. hormozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatment are not appropriate.

DUOTRAV 以色列 - 英文 - Ministry of Health

duotrav

novartis israel ltd - timolol as maleate; travoprost - ophthalmic solution - travoprost 40 mcg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intraocular pressure (iop) in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

AZARGA 以色列 - 英文 - Ministry of Health

azarga

novartis israel ltd - brinzolamide; timolol as maleate - ophthalmic suspension - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

MABTHERA 10 MGML I.V 以色列 - 英文 - Ministry of Health

mabthera 10 mgml i.v

roche pharmaceuticals (israel) ltd - rituximab - concentrate for solution for infusion - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plus chemotherapy.* rheumatoid arthritismabthera is indicated, in combination with methotrexate, to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to one or more tnf antagonist therapies.* granulomatosis with polyangiitis and microscopic polyangiitismabthera, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (gpa) (wegener’s granulomatosis (wg) and microscopic polyangiitis (mpa). *pemphigus vulgarismabthera is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (pv).